Volume: 45 Issue: 3
Review on chemistry, pharmacology, toxicity and future prospectives of withaferin A
Year: 2023, Page: 108-122, Doi: https://doi.org/10.62029/jmaps.v45i3.shukla
Received: Dec. 7, 2023 Accepted: Dec. 19, 2023 Published: Dec. 31, 2023
The medicinal plant Withania somnifera is widely researched for its antiinflammatory,cardioprotective, and anticancer effects. W. somnifera preparations are specifically used to treat menstruation issues and arthritis in Ayurveda, the main traditional Indian medical system. The bioactive substance withaferin A (WA), a steroidal lactone, was first isolated from the leaves of W. somnifera. Numerous studies showed that WA contains various pharmacological properties, making it a good choice for treating various diseases. Its structural modification targets several signal transduction pathways and improves the effectiveness of treatment for a range of illnesses. We comprehensively reviewed withaferin A and its pharmacological activities against various diseases. Among the most well-studied effects of withaferin A are anticancer properties, including breast cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer, multiple myeloma, neuroblastoma, leukaemia, and glioblastoma, where WA have shown the potential anticancer effect. The studies demonstrated that WA inhibits the growth and metastasis of several cancer cell lines. The current review thoroughly analyses the pharmacokinetics, biological activities, and changes of several disease targets linked to WA.
Keywords: Biosynthesis, Pharmacology, Toxicity, Withaferin A, Withania somnifera
Agarwalla P, Mukherjee S, Sreedhar B, Banerjee R. 2016. Glucocorticoid receptor-mediated delivery of nano gold–withaferin conjugates for reversal of epithelial-to-mesenchymal transition and tumor regression. Nanomed 11: 2529-2546.
Aminu N, Bello I, Umar NM, Tanko N, Aminu A, Audu MM. 2020. The influence of nanoparticulate drug delivery systems in drug therapy. J Drug Delivery Sci Technol 60: 101961.
Atluri VSR, Tiwari S, Rodriguez M, Kaushik A, Yndart A, Kolishetti N, Nair M. 2020. Inhibition of amyloid-beta production, associated neuroinflammation, and histone deacetylase 2-mediated epigenetic modifications prevent neuropathology in alzheimer’s disease in vitro model. Front in Aging Neurosci 11: 342.
Atteeq M. 2022. Evaluating anticancer properties of Withaferin A: A potent phytochemical. Front Pharmacol 13: 975320.
Bargagna-Mohan P, Hamza A, Kim Y-e, Ho YKA, Mor-Vaknin N, Wendschlag N, Zhan C-G. 2007. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 14: 623-634.
Bartkova J, Hoøejší Z, Koed K, Krämer A, Tort F, Zieger K, Lukas C. 2005. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nat 434: 864-870.
Berghe WV, Sabbe L, Kaileh M, Haegeman G, Heyninck K. 2012. Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol 84: 1282-1291.
Bhat WW, Lattoo SK, Razdan S, Dhar N, Rana S, Dhar RS, Vishwakarma RA. 2012. Molecular cloning, bacterial expression, and promoter analysis of squalene synthase from Withania somnifera (L.) Dunal. Gene 499: 25-36.
C Deocaris C, Lu W.-J, C Kaul S, Wadhwa R. 2013. Druggability of mortal in for cancer and neurodegenerative disorders. Curr Pharm Design 19: 418-429.
Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M. 2014. Targeting metastatic castration-resistant prostate cancer: Mechanisms of progression and novel early therapeutic approaches. Expert Opin Invest Drugs 23: 469-487.
Chakraborty S, Mallick D, Goswami M, Guengerich FP, Chakrabarty A, Chowdhury G. 2022. The natural products withaferin A and withanone from the medicinal Herb Withania somnifera are covalent inhibitors of the SARS-CoV-2 main protease. J Nat Prod 85: 2340-2350.
Chatterjee S, Srivastava S, Khalid A, Singh N, Sangwan RS, Sidhu OP, Tuli R. 2010. Comprehensive metabolic fingerprinting of Withania somnifera leaf and root extracts. Phytochem 71: 1085-1094.
Chaudhary A, Kalra RS, Malik V, Katiyar SP, Sundar D, Kaul SC, Wadhwa R. 2019. 2, 3-Dihydro-3âmethoxy Withaferin-A lacks anti-metastasis potency: Bioinformatics and experimental evidence. Sci Rep 9: 17344.
Choudhary MI, Yousuf S, Nawaz SA, Ahmed S. 2004. Cholinesterase inhibiting withanolides from Withania somnifera. Chem Pharm Bull 52: 1358-1361.
Dai T, Jiang W, Guo Z, Wang Z, Huang M, Zhong G, Dai R. 2019. Studies on oral bioavailability and first‐pass metabolism of withaferin A in rats using LC–MS/MS and Q‐TRAP. Biomed Chromatogr 33: e4573.
Das T, Roy KS, Chakrabarti T, Mukhopadhyay S, Roychoudhury S. 2014. Withaferin A modulates the spindle assembly checkpoint by degradation of Mad2–Cdc20 complex in colorectal cancer cell lines. Biochem Pharmacol 91: 31-39.
Devkar ST, Kandhare AD, Sloley BD, Jagtap SD, Lin J, Tam YK, Hegde MV. 2015. Evaluation of the bioavailability of major withanolides of Withania somnifera using an in vitro absorption model system. J Adv Pharm Technol & Res 6: 159.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
Fong MY, Jin S, Rane M, Singh RK, Gupta R, Kakar SS. 2012. Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. Plos One 7: 1-16.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24: 908-922.
Fuska J, Fuskova A, Rosazza J, Nicholas A. 1984. Novel cytotoxic and antitumor agents. IV. Withaferin A: Relation of its structure to the in vitro cytotoxic effects on P388 cells. Neoplasma 31: 31-36.
Grin B, Mahammad S, Wedig T, Cleland MM, Tsai L, Herrmann H, Goldman RD. 2012. Withaferin alters intermediate filament organization, cell shape, and behavior. PloS One 7: e39065.
Guo R, Gan L, Lau WB, Yan Z, Xie D, Gao E, Wang Y. 2019. Withaferin A prevents myocardial ischemia/reperfusion injury by upregulating AMP-activated protein kinase-dependent B-cell lymphoma2 signaling. Circulation J 83: 1726-1736.
Gupta RC, Bansal SS, Aqil F, Jeyabalan J, Cao P, Kausar H, Vadhanam MV. 2012. A controlledrelease systemic delivery new concept in cancer chemoprevention. Carcinog 33: 1608-1615.
Hahm E.-R, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. 2011. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PloS One 6: e23354.
Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Choi SM. 2018. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. The J Clin Invest 128: 3341-3355.
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Tzeng T.-C. 2013. NLRP3 is activated in alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nat 493: 674-678.
Huang C, Vaishnavi K, Kalra R, Zhang Z, Sekar K, Kaul S, Wadhwa R. 2015. 3beta-methoxy derivation of Withaferin-A attenuates its anticancer potency: Bioinformatics and molecular evidence. Med Aromat Plants 4: 2167-0412.100021.
Johny L, Conlan X, Cahill D, Adholeya A. 2015. In vitro and situ screening systems for morphological and phytochemical analysis of Withania somnifera germplasms. Pl Cell Tissue Organ Cult 120: 1191-1202.
Kabir MT, Uddin MS, Jeandet P, Emran TB, Mitra S, Albadrani GM, Simal-Gandara J. 2021. Antialzheimer’s molecules derived from marine life: Understanding molecular mechanisms and therapeutic potential. Mar Drugs 19: 251.
Kakar SS, Parte S, Carter K, Joshua IG, Worth C, Rameshwar P, Ratajczak MZ. 2017. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget 8: p.74494.
Kelm NQ, Straughn AR, Kakar SS. 2020. Withaferin A attenuates ovarian cancer-induced cardiac cachexia. PloS One 15: e0236680.
Khalilpourfarshbafi M, Devi Murugan D, Abdul Sattar MZ, Sucedaram Y, Abdullah NA. 2019. Withaferin A inhibits adipogenesis in the 3T3-F442A cell line, improves insulin sensitivity, and promotes weight loss in high-fat diet-induced obese mice. PloS One 14: e0218792.
Khedgikar V, Kushwaha P, Gautam J, Verma A, Changkija B, Kumar A, Trivedi P. 2013. Withaferin A: A proteasomal inhibitor that promotes healing after injury and exerts an anabolic effect on osteoporotic bone. Cell Death Dis 4: e778-e778.
Kim S.-H, Hahm E.-R, Singh KB, Shiva S, Stewart-Ornstein J, Singh SV. 2020. RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells. Carcinog 41: 778-789.
Kreso A, Dick JE. 2014. Evolution of the cancer stem cell model. Cell Stem Cell 14: 275-291.
Kyakulaga AH, Aqil F, Munagala R, Gupta RC. 2018. Withaferin A inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells. Sci Rep 8: 15737.
Lee J, Hahm ER, Singh SV. 2010. Withaferin A inhibits the activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinog 31: 1991-1998.
Li X, Zhu F, Jiang J, Sun C, Wang X, Shen M, Peng F. 2015. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Lett 357: 219-230.
Liu W, Wang G, Palovcak A, Li Y, Hao S, Liu ZJ, Zhang Y. 2019. Impeding the single-strand annealing pathway of DNA double-strand break repair by withaferin A-mediated FANCA degradation. DNA Repair 77: 10-17.
Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, Chiariello M. 2003. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circ 108: 1455-1460.
Luo Y, Cui X, Zhao J, Han Y, Li M, Lin Y, Lan L. 2014. Cells susceptible to epithelial-mesenchymal transition are enriched in stem-like side population cells from prostate cancer. Oncol Rep 31: 874-884.
Meena AK, Rekha P, Perumal A, Gokul M, Swathi K, Ilavarasan R. 2021. Estimation of Withaferin-A by HPLC and standardization of the Ashwagandha lehyam formulation. Heliyon 7.
Michelotti GA, Machado MV, Diehl AM. 2013. NAFLD, NASH, and liver cancer. Nat Rev Gastroenterology & Hepatology 10: 656-665.
Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. 2009. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Mol 14: 2373-2393.
Moncrief JW, Heller KS. 1967. Acylation: A proposed mechanism of action for various oncolytic agents based on model chemical systems. Cancer Res 27: 1500-1502.
Moselhy J, Suman S, Alghamdi M, Chandarasekharan B, Das TP, Houda A, Damodaran C. 2017. Withaferin A inhibits prostate carcinogenesis in a PTEN-deficient mouse model of prostate cancer. Neoplasia 19: 451-459.
Narayan M, Zhang J, Braswell K, Gibson C, Zitnyar AC, Lee DK, Jinwal U. 2015. Withaferin A regulates LRRK2 levels by interfering with the Hsp90-Cdc37 chaperone complex. Curr Aging Sci 8: 259-265.
O'Regan RM, Jordan VC. 2002. The evolution of tamoxifen therapy in breast cancer: selective estrogen-receptor modulators and downregulators. The Lancet Oncol 3: 207-214.
Pal D, Tyagi A, Chandrasekaran B, Alattasi H, Ankem MK, Sharma AK, Damodaran C. 2018. Suppression of Notch1 and AKT mediated epithelial to mesenchymal transition by Verrucarin J in metastatic colon cancer. Cell Death Dis 9: 798.
Patel DP, Yan T, Kim D, Dias HB, Krausz KW, Kimura S, Gonzalez FJ. 2019. Withaferin A improves non-alcoholic steatohepatitis in mice. J Pharmacol Exp Ther 371: 360-374.
Patel SB, Rao NJ, Hingorani LL. 2016. Safety assessment of Withania somnifera extract standardized for Withaferin A: Acute and sub-acute toxicity study. J Ayurveda Integr Med 7: 30-37.
Patil D, Gautam M, Mishra S, Karupothula S, Gairola S, Jadhav S, Patwardhan B. 2013. Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatographytandem mass spectrometry: Application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. J Pharm Biomed Anal 80: 203-212.
Pires N, Gota V, Gulia A, Hingorani L, Agarwal M, Puri A. 2020. Safety and pharmacokinetics of Withaferin-A in advanced stage high-grade osteosarcoma: A phase I trial. J Ayurveda Integr Med 11: 68-72.
Prabu P, Panchapakesan S, Raj CD. 2013. Acute and sub‐acute oral toxicity assessment of the hydroalcoholic extract of Withania somnifera roots in Wistar rats. Phytotherapy Res 27: 1169-1178.
Rabhi C, Arcile G, Le Goff G, Da Costa Noble C, Ouazzani J. 2019. Neuroprotective effect of CR-777, a glutathione derivative of Withaferin A, obtained through the bioconversion of Withania somnifera (L.) Dunal extract by the fungus Beauveria bassiana. Mol 24: 4599.
Raziya Banu M, Ibrahim M, Prabhu K, Rajasankar S. 2020. Withaferin-A protects the nigral dopamine neuron and recovers motor activity in aged rats. Cells Tissues Organs 208: 59-65.
Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA. 2008. Inhibition of AMP-activated protein kinase protects pancreatic â-cells from cytokine-mediated apoptosis and CD8+ T-cell–induced cytotoxicity. Diabetes 57: 415-423.
Rona G. 1985. Catecholamine cardiotoxicity. J Mol and Cell Cardiol 17: 291-306.
Santagata S, Xu Y.-m, Wijeratne EK, Kontnik R, Rooney C, Perley CC, Whitesell L. 2012. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol 7: 340-349.
Shah HS, Usman F, Ashfaq–Khan M, Khalil R, Ul-Haq Z, Mushtaq A, Iqbal J. 2020. Preparation and characterization of anticancer liposomal withaferin–A formulation for improved delivery to cancer cells: In vitro, in vivo, and silico evaluation. J Drug Delivery Sci Technol 59: 101863.
Singh S, Pal S, Shanker K, Chanotiya CS, Gupta MM, Dwivedi UN, Shasany AK. 2014. Sterol partitioning by HMGR and DXR for routing intermediates toward withanolide biosynthesis. Physiol Plant 152: 617-633.
Sivasankarapillai VS, Madhu Kumar Nair R, Rahdar A, Bungau S, Zaha DC, Aleya L, Tit DM. 2020. Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera. Environ Sci and Pollut Res 27: 26025-26035.
Sohat B, Gitter E, Abraham A, Lavie D. 1967. Antitumor activity of withaferin A. Cancer Chemother Rep 51: 51271-51276.
Stan SD, Zeng Y, Singh SV. 2008. Ayurvedic medicine constituent withaferin causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 60: 51-60.
Straughn AR, Kakar SS. 2019. Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling. J Ovarian Res 12: 1-14.
Sultana F, Neog MK, Rasool M. 2017. Withaferin-A, a steroidal lactone encapsulated mannose decorated liposomes ameliorates rheumatoid arthritis by intriguing the macrophage repolarization in adjuvant-induced arthritic rats. Colloids Surf B: Biointerfaces 155: 349-365.
Suman S, Das TP, Moselhy J, Pal D, Kolluru V, Alatassi H, Damodaran C. 2016. Oral administration of withaferin A inhibits carcinogenesis of the prostate in the TRAMP model. Oncotarget 7: 53751.
Tekula S, Khurana A, Anchi P, Godugu C. 2018. Withaferin-A attenuates multiple low doses of streptozotocin (MLD-STZ) induced type 1 diabetes. Biomed Pharmacotherapy 106: 1428-1440.
Thirugnanasambantham P, Roy IM, Charles SN, Senthil K. 2014. Ontogenetic assessment of withanolide biogenesis and expression of selected pathway genes in Withania somnifera, a traditional medicinal herb. J Pharm Res 8: 1344-1351.
Tit DM, Bungau S, Iovan C, Nistor Cseppento DC, Endres L, Sava C, Furau C. 2018. Effects of the hormone replacement therapy and soy isoflavones on bone resorption in postmenopause. J Clin Med 7: 297.
Tiwari S, Atluri VSR, Yndart Arias A, Jayant RD, Kaushik A, Geiger J, Nair MN. 2018. Withaferin a suppresses beta-amyloid in APP expressing cells: studies for tat and cocaine-associated neurological dysfunctions. Front Aging Neurosci 10: 291.
Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, Zaha DC. 2020. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics 10: 314.
Walle T. 2009. Methylation of dietary flavones increases their metabolic stability and chemopreventive effects. Int J Mol Sci 10: 5002-5019.
Xu K, Shi H, Du Y, Ou J. 2021. Withaferin A inhibits the proliferation of human endometrial cancer cells via transforming growth factor-â (TGF-â) signaling. Biotech 11: 323.
Yokota Y, Bargagna-Mohan P, Ravindranath PP, Kim KB, Mohan R. 2006. Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett 16: 2603-2607.
Yousefian Z, Hosseini B, Rezadoost H, Palazón J, Mirjalili MH. 2018. Production of the anticancer compound withaferin from genetically transformed hairy root cultures of Withania somnifera. Nat Prod Commun 13: 943-948.
Yousuf SK, Majeed R, Ahmad M, lal Sangwan P, Purnima B, Saxsena A, Taneja SC. 2011. Ring A structurally modified derivatives of withaferin A and the evaluation of their cytotoxic potential. Steroids 76: 1213-1222.
Zhang X, Samadi AK, Roby KF, Timmermann B, Cohen MS. 2012. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecologic Oncol 124: 606-612.
Zomborszki ZP, Peschel W, Boros K, Hohmann J, Csupor D. 2016. Development of an optimized processing method for withania frutescens. Acta Alimentaria 45: 452-456.
© CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow-226015
Shukla A, Srivastava S, Dev K. 2023. Review on chemistry, pharmacology, toxicity and future prospectives of withaferin A. J Med Aromat Plant Sci 45: 108-122.
